Introduction
Since resistance of many tumors to established treatment regimens still constitutes a major concern in oncology, attempts to improve the survival of cancer patients largely depend on strategies to target tumor cell resistance (Peto, 2001) . Induction of apoptosis in cancer cells is a key killing mechanism for most antitumor therapies including chemotherapy, g-irradiation, immunotherapy or cytokines. Thus, defects in apoptosis programs may cause resistance (Hengartner, 2000; Lowe and Lin, 2000; Johnstone et al., 2002) . Apoptosis pathways may be initiated through different entry sites, such as death receptors (receptor pathway) or mitochondria (mitochondrial pathway) resulting in activation of effector caspases (Hengartner, 2000) . Stimulation of death receptors of the tumor necrosis factor (TNF) receptor superfamily such as CD95 (APO-1/Fas) results in receptor aggregation and recruitment of the adaptor molecule Fas-associated death domain (FADD) and caspase-8 (Ashkenazi, 2002) . Upon recruitment, caspase-8 becomes activated and initiates apoptosis by direct cleavage of downstream effector caspases. A second pathway is initiated at the mitochondrial level. Upon induction of apoptosis, apoptogenic factors such as cytochrome c, apoptosis-inducing factor (AIF) or Smac/DIABLO are released from mitochondria into the cytosol. Cytochrome c triggers caspase-3 activation through formation of the cytochrome c/Apaf-1/caspase-9-containing apoptosome complex, while Smac/ Diablo promotes caspase activation through neutralizing the inhibitory effects to inhibitor of apoptosis proteins (IAPs) (van Loo et al., 2002) . Signals originating from the CD95 receptor may be linked to mitochondria by Bid, a BH3 domain-containing protein of the Bcl-2 family which assumes cytochrome-creleasing activity upon cleavage by caspase-8, thereby initiating a mitochondrial amplification loop (van Loo et al., 2002) .
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), a member of the TNF family of death ligands, is a promising candidate for cancer therapy, because it induces apoptosis in a broad spectrum of cancer cell lines and also exhibits potent tumoricidal activity in several xenograft models in vivo (LeBlanc and Ashkenazi, 2003) . Unlike the other death ligands CD95 or TNFa, systemic administration of soluble human TRAIL did not cause systemic toxicity in mice or nonhuman primates, although some concerns about potential toxic side effects of TRAIL on normal human cells have recently been raised (Jo et al., 2000; Nitsch et al., 2000) . The potential application of TRAIL for cancer therapy is, however, hampered by the fact that many tumors remain resistant towards treatment with TRAIL, which may be caused by dominance of antiapoptotic programs (LeBlanc and Ashkenazi, 2003) .
We previously reported a cell type-dependent (type I and type II) organization of the TRAIL signaling pathway similar to the CD95 pathway (Scaffidi et al., 1998; Fulda et al., 2002) . Type I cells initiate and execute death receptor-triggered apoptosis entirely via formation of a death-inducing signaling complex (DISC), resulting in caspase-8 processing and activation of effector caspases (Scaffidi et al., 1998) . In contrast, type II cells show minimal DISC formation and depend on amplification of the death signal through the mitochondrial pathway for full activation of the caspase cascade and cell death (Scaffidi et al., 1998) . Accordingly, blockade of the mitochondrial pathway by Bcl-2 inhibited TRAIL-induced apoptosis in type II cells (Fulda et al., 2002) . This cell type-dependent (type I and type II) organization of the TRAIL signaling pathway is of special interest for the use of TRAIL in cancer therapy, since the majority of tumors fall into the category of type II cells (Algeciras-Schimnich et al., 2003) . We therefore asked whether triggering of the mitochondrial pathway may lower the threshold of TRAIL to induce apoptosis in cancer cells. To address this question, we used betulinic acid (BetA), a mitochondriotropic cytotoxic compound, which induces apoptosis in tumor cells by triggering the mitochondrial pathway (Pisha et al., 1995; Fulda et al., 1998a, b; Selzer et al., 2000; Zuco et al., 2002) . Here, we report for the first time that simultaneous stimulation of the extrinsic (death receptor) pathway by TRAIL and the intrinsic (mitochondrial) pathway by BetA cooperated through functional complementation to induce apoptosis in tumor cells.
Results

BetA and TRAIL cooperate to induce apoptosis in tumor cells
In search for novel strategies to enhance the efficacy of TRAIL-based regimens, we investigated the effect of the mitochondriotropic anticancer drug betulinic acid on TRAIL-induced apoptosis. For these studies, we selected SHEP neuroblastoma cells, which have previously been proven suitable for studies on apoptosis pathways by our group and by other investigators (Fulda et al., 1998a, b; Kim and Feldman, 2002) .
Treatment of SHEP neuroblastoma cells with relatively low doses of either the death ligand TRAIL or BetA alone induced only minimal apoptosis (Figure 1a-c) . Interestingly, the combined treatment with BetA together with TRAIL strongly cooperated to induce apoptosis in SHEP neuroblastoma cells in a dose and time-dependent manner, as determined by analysis of Figure 1 Effect of BetA on TRAIL-induced apoptosis. (a-c) Cooperation of BetA and TRAIL to induce apoptosis. SHEP neuroblastoma cells were treated for 12-48 h with 0-8 mg/ml BetA and/or 0-10 ng/ml TRAIL (0 ng/ml: white bars, 1 ng/ml: vertically hatched bars, 3 ng/ml: horizontally hatched bars, 10 ng/ml: black bars). Figure 1d ). Since combinations of cytotoxic agents may give rise to different effects depending on treatment schedules, we tested whether the treatment schedules of BetA and TRAIL might influence the cooperative effect. Sequential treatment with BetA for 12 h followed by TRAIL for 12 h or with TRAIL for 12 h followed by BetA for 12 h yielded less apoptosis than cotreatment with BetA and TRAIL for 24 h (data not shown). To exclude that the sensitization effect of BetA was restricted to the death ligand TRAIL, we tested BetA in various combination treatments. Also, BetA sensitized SHEP neuroblastoma cells for CD95-or TNFa-induced apoptosis ( Figure 2 ). We then extended our studies to additional human cancer cell lines to exclude that the cooperative effect of BetA and TRAIL was restricted to a particular cell line. Importantly, BetA sensitized neuroblastoma, medulloblastoma, glioblastoma or melanoma cells for TRAIL-induced apoptosis ( Figure 3a ). We also included normal human fibroblast in our studies, since we were concerned that BetA might reverse the lack of toxicity of TRAIL to nonmalignant cells. Notably, BetA failed to sensitize untransformed human fibroblast for TRAIL-induced apoptosis indicating some tumor specificity ( Figure 3a) . Furthermore, we extended our studies to primary tumor cells derived from metastatic renal cell carcinoma. Interestingly, we found that BetA sensitized renal cell carcinoma cells for TRAIL-induced apoptosis ( Figure 3b ). Together, this set of experiments indicates that BetA cooperated with death receptor ligands to trigger apoptosis in different human tumor cell lines and primary tumor cells, but not in nonmalignant human cells.
BetA and TRAIL cooperate to activate caspases
To see whether apoptosis upon treatment with BetA and TRAIL was the result of caspase activation, we used the broad-range caspase inhibitor zVAD.fmk (benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone). Apoptosis in response to treatment with BetA and TRAIL was almost completely blocked in the presence of zVAD.fmk, demonstrating that apoptosis was mediated by activation of caspases ( Figure 4a ). We then monitored activation of caspases by Western blot analysis to see whether and at what level of the caspase cascade the BetA-and TRAIL-induced signaling pathways converged. Single agent treatment with TRAIL resulted in limited activation of caspase-8 and -3, while single agent treatment with BetA led to limited cleavage of caspase-9 ( Figure 4b ). Notably, only the combined treatment with BetA and TRAIL resulted in full activation of the effector caspase-3, as indicated by almost complete turnover of caspase-3 proenzyme ( Figure 4b ). Also, cleavage and thus inactivation of Xlinked inhibitor of apoptosis (XIAP), an endogenous caspase inhibitor, was only observed upon combination treatment with BetA and TRAIL ( Figure 4b ). Interestingly, BetA and TRAIL also cooperated to cleave Bid and caspase-8 indicating that activated effector caspases may feed back to activate caspase-8 and Bid, thereby amplifying the death signal ( Figure 4b ). To directly assess caspase activity, we also performed an enzymatic caspase assay using fluorogenic caspase substrates. Cotreatment with BetA and TRAIL resulted in increased caspase-3, caspase-9 and caspase-8 activity compared to either treatment alone (Figure 4c -e). Cooperation of betulinic acid and TRAIL S Fulda et al Interestingly, the increase in caspase-3 activity preceded the increase in caspase-8 activity (Figure 4c and e), further supporting the notion that caspase-8 was activated in a feedback amplification loop upon combined treatment with BetA and TRAIL, for example, by caspase-3. Highest caspase activity as Figure 4 Cooperation of BetA and TRAIL to activate caspases. (a) Effect of caspase inhibition on BetA and TRAIL-induced apoptosis. SHEP neuroblastoma cells were treated for 24 h with 5 mg/ml BetA and/or 10 ng/ml TRAIL in the presence or absence of 50 mM zVAD.fmk. Apoptosis was determined by FACS analysis of DNA fragmentation of propidium-iodide-stained nuclei. Mean and s.d. of triplicates are shown; similar results were obtained in three independent experiments. (b-e) Effect of BetA on TRAIL-induced caspase activation. SHEP neuroblastoma cells were treated for 2-24 h with 5 mg/ml BetA and/or 10 ng/ml TRAIL. Expression of caspase-2, -3, -6, -8, -9, Bid, XIAP and a-tubulin was assessed by Western blot analysis (b). Cleavage products are indicated by arrows and nonspecific immune-reactive bands are indicated by asterisk. In (c-e), caspase activity of cells treated for 2-24 h with 5 mg/ml BetA and/or 10 ng/ml TRAIL was determined by enzymatic assay using fluorogenic caspase substrates as described in Materials and methods. X-fold increase in caspase activity compared to untreated controls is shown. Mean and s.d. of triplicates are shown; similar results were obtained in three independent experiments
Cooperation of betulinic acid and TRAIL S Fulda et al detected by enzymatic assay did not always correlate with caspase cleavage as determined by Western blot analysis, which may be related to the fact that caspase cleavage products are subject to degradation by the proteasome (Zhang et al., 2004) . Together, this set of experiments demonstrates that BetA and TRAIL cooperated to activate effector caspases.
BetA and TRAIL cooperate to perturb mitochondrial functions
We next analysed the effect of BetA and TRAIL on mitochondrial function, since BetA has been reported to directly trigger mitochondrial perturbations. Combined treatment with BetA and TRAIL resulted in enhanced breakdown of mitochondrial membrane potential compared to either treatment alone (Figure 5a ). To further address the role of mitochondria in BetA-and TRAILinduced apoptosis, we determined the release of cytochrome c from mitochondria by flow cytometry, staining cytochrome c in permeabilized cells. BetA and TRAIL acted in concert to trigger cytochrome c release from mitochondria compared to either treatment alone (Figure 5b ). In addition, we analysed translocation of mitochondrial proteins into the cytosol by Western blot analysis of mitochondrial and cytosolic cell fractions. Increased release of cytochrome c and Smac from mitochondria into the cytosol was observed in cells treated with BetA and TRAIL compared to cells treated with BetA or TRAIL alone (Figure 5c ). To test whether loss of mitochondrial membrane potential and cytochrome c release upon treatment with BetA and TRAIL required caspase activity, we used the broad-range caspase inhibitor zVAD.fmk. Upon treatment with TRAIL, loss of mitochondrial membrane potential and cytochrome c release was completely inhibited by addition of zVAD.fmk (Figure 5d and e). Interestingly, loss of mitochondrial membrane potential and cytochrome c release following treatment with BetA alone or with the combination of BetA and TRAIL was strongly, but not completely reduced in the presence of zVAD.fmk (Figure 5d and e). This indicates that loss of mitochondrial membrane potential and cytochrome c release upon combined treatment with BetA and TRAIL involved caspase-dependent and also caspase-independent mechanisms. Since loss of mitochondrial membrane potential and cytochrome c release upon treatment with subtoxic doses of BetA partially required caspase activity, these findings suggest that mitochondrial perturbations following subtoxic doses of BetA involved a caspase-dependent amplification loop.
Overexpression of Bcl-2 inhibits apoptosis induced by BetA and TRAIL
Our findings obtained so far suggest that the cooperative effect of BetA and TRAIL involved a mitochondrial amplification step. To investigate whether mitochondrial perturbations were in fact required for the cooperative effect of BetA and TRAIL, we used SHEP neuroblastoma cells transfected with Bcl-2. Overexpression of Bcl-2 inhibited loss of mitochondrial membrane potential following treatment with BetA, with TRAIL or with the combination of BetA and TRAIL (Figure 6a and b). Also, overexpression of Bcl-2 inhibited release of cytochrome c from mitochondria upon treatment with BetA and/or TRAIL (Figure 6c and d) . Importantly, overexpression of Bcl-2 inhibited apoptosis upon treatment with BetA and/or TRAIL (Figure 7) . Also, loss of clonogenic survival upon treatment with BetA and/or TRAIL was inhibited in Bcl-2-overexpressing SHEP neuroblastoma cells compared to vector control cells (data not shown). This indicates that the cooperative effect of BetA and TRAIL depended on signaling through the mitochondrial pathway.
Discussion
Since most anticancer therapies including chemotherapy primarily act by inducing apoptosis in cancer cells, defects in apoptosis programs may cause resistance (Johnstone et al., 2002) . The idea to specifically target death receptors to trigger apoptosis in tumor cells is attractive for cancer therapy, since death receptors have a direct link to the cell's death machinery (Ashkenazi, 2002) . To this end, TRAIL appears to be a relatively safe and promising death ligand for clinical application. However, many tumors remain resistant towards TRAIL despite expression of both agonistic TRAIL receptors, which has been related to the dominance of antiapoptotic signals, for example, those delivered by NFkB, AKT or by IAPs (Ashkenazi, 2002) . Also, induction of cell death upon TRAIL receptor ligation is frequently incomplete and tends to select for rapid outgrowth of TRAIL-resistant tumor cells (Ashkenazi, 2002) . We previously found that TRAIL-induced apoptosis requires amplification by mitochondria for activation of downstream effector systems, at least in certain cell types such as type II cells (Fulda et al., 2002) . Since the vast majority of tumors fall into the category of type II cells, this mitochondrial amplification loop is of special relevance for the use of TRAIL in cancer therapy. We therefore asked whether the mitochondriotropic anticancer drug betulinic acid, which directly induces mitochondrial perturbations , would modulate the sensitivity of tumor cells for TRAILinduced apoptosis. We provide for the first time evidence that combined treatment with BetA and TRAIL cooperated to induce apoptosis in tumor cells, for example, type II cells. Importantly, the combination treatment with BetA and TRAIL not simply delayed tumor growth, but inhibited clonogenic survival of tumor cells.
Analysis of signaling pathways mediating this cooperative effect of BetA and TRAIL revealed that simultaneous stimulation of the extrinsic (death receptor) pathway by TRAIL and the intrinsic (mitochondrial) pathway by BetA resulted in enhanced activation of effector caspases and enhanced tumor cell kill through functional complementation. Single agent treatment with suboptimal concentrations of TRAIL induced minimal activation of caspase-8 and minimal mitochondrial alterations, however, did not translate into full activation of the effector caspase-3 or into cleavage of endogenous caspase inhibitors such as XIAP. Also, single agent treatment with subtoxic concentrations of BetA did not lead to activation of the effector caspase-3, although it resulted in minimal loss of mitochondrial membrane potential, release of cytochrome c and caspase-9 activation. Importantly, simultaneous triggering of the extrinsic (death receptor) (c) Effect of BetA and TRAIL on release of mitochondrial proteins. SHEP neuroblastoma cells were treated for 2-12 h with 5 mg/ml BetA and/or 10 ng/ml TRAIL. Expression of Smac, cytochrome c or COX4 in the mitochondrial (M) or cytosolic (C) fraction was assessed by Western blot analysis. (d, e) Effect of caspase inhibition on BetA and TRAIL-induced loss of mitochondrial membrane potential and cytochrome c release. SHEP neuroblastoma cells were treated for 2-24 h with 5 mg/ml BetA and/or 10 ng/ml TRAIL in the presence of 50 mM zVAD.fmk. In (d), mitochondrial membrane potential (MMP) was assessed by flow cytometry using the fluorescent dye DiOC 6 (3). In (e), release of cytochrome c from mitochondria was assessed by flow cytometry, staining cytochrome c in permeabilized cells as described in Materials and methods. Mean and s.d. of triplicates are shown; similar results were obtained in three independent experiments Cooperation of betulinic acid and TRAIL S Fulda et al pathway by TRAIL and the intrinsic (mitochondrial) pathway by BetA cooperated to trigger loss of mitochondrial membrane potential, translocation of cytochrome c and Smac from mitochondria into the cytosol, full activation of caspase-3, downregulation of XIAP and cell death. Mitochondrial perturbations in response to TRAIL receptor ligation may result from activation of caspase-8 and cleavage of Bid, which in turn translocates to mitochondria and triggers cytochrome c release. Following treatment with BetA, loss of mitochondrial membrane potential may be due to a direct effect of BetA on the mitochondrial permeability pore complex, which is involved in the regulation of cytochrome c release (van Loo et al., 2002) . Interestingly, enhanced loss of mitochondrial membrane potential and enhanced cytochrome c release found upon combined treatment with BetA and TRAIL partially depended on caspase activity, since those alterations were partially blocked by the caspase inhibitor zVAD.fmk. This indicates that the combination treatment with BetA and TRAIL induced mitochondrial perturbations through functional complementation in a caspase-dependent and also in a caspase-independent manner. Combination treatment with BetA and TRAIL also resulted in increased activation of caspase-8 and cleavage of Bid indicating that activation of effector caspases may feed back to promote activation of caspase-8 and cleavage of Bid. Cleaved Bid may further promote mitochondrial dysfunctions in a positive amplification loop by triggering cytochrome c release. Importantly, the combination treatment with BetA and TRAIL cooperated to induce apoptosis in different tumor cell lines and also in primary tumor cells. Also, the sensitizing effect of BetA for apoptosis was not restricted to TRAIL, but also found in response to treatment with TNFa or following CD95 ligation. There are several reports on the synergistic effect of TRAIL and conventional DNA-damaging cytotoxic Cooperation of betulinic acid and TRAIL S Fulda et al drugs or g-irradiation (Gliniak and Le, 1999; Chinnaiyan et al., 2000; Keane et al., 2000; Nagane et al., 2000; Belka et al., 2001; Rohn et al., 2001) . The molecular mechanisms, which account for this synergistic interaction may include transcriptional upregulation of the agonistic TRAIL receptors TRAIL-R1 and TRAIL-R2, which may occur in a p53-dependent manner (Takimoto and ElDeiry, 2000; Meng and El-Deiry, 2001 ). Notably, cooperation of TRAIL and BetA to induce apoptosis occurred in both p53 wild-type and p53 mutant cells without accumulation of wild-type p53 protein ( and data not shown). Also, we found no increase in expression of TRAIL-R1 or TRAIL-R2 upon treatment with BetA (data not shown). These findings indicate that the functional basis for cooperation between TRAIL and BetA may be distinct from mechanisms previously reported for TRAIL and DNA-damaging drugs. Thus, combined treatment with BetA and TRAIL may even be effective in tumors harboring p53 mutations, which are often resistant to conventional cytotoxic drugs.
The rational for combination therapies is based on the concept that triggering tumor cell apoptosis via distinct entry sites, for example, through the extrinsinc (death receptor) and intrinsic (mitochondrial) pathway, may help to amplify weaker death signals and ensure that apoptosis occurs within a certain time frame. Thus, combination treatment may prove to be advantageous in malignancies that still partially respond to either treatment alone, since it potentially diminish the pool of tumor cells that give rise to an outgrowing resistant variant of the parental tumor and may therefore constitute a potent strategy for bypassing resistance. In this respect, the level at which anticancer drugs act in apoptosis signaling pathways is likely to have some impact for treatment response. Mitochondrial alterations constitute a critical event in the process leading to drug-induced apoptosis . Most conventional chemotherapeutic agents, however, elicit mitochondrial permeabilization in an indirect fashion by triggering endogenous signal transduction pathways, for example, activation of the DNA damage response pathway involving p53 activation, which then affects mitochondria and induces cell death. Thus, a current problem of conventional chemotherapeutic agents may result from the fact that these endogenous apoptosisinduction pathways are often altered in tumor cells, for example, by p53 mutations. On theoretical grounds, agents that act on a more downstream level of apoptosis control by directly initiating mitochondria-dependent signaling pathways may be advantageous for treating tumors in which such upstream signal transduction pathways are interrupted. Therefore, the combination of mitochondria-targeting drugs such as BetA and the death receptor ligand TRAIL may be advantageous compared to combined treatment of conventional anticancer drugs and TRAIL under certain circumstances, for example, for tumors harboring p53 mutations. However, employing the mitochondria pathway to enhance the efficacy of TRAIL treatment may be less effective in other tumors, for example, those expressing high levels of Bcl-2.
Our findings may have several implications, for example, for the proposed use of TRAIL in cancer therapy. Recombinant soluble TRAIL or agonistic TRAIL receptor antibodies are promising candidates for cancer therapy, because they induce apoptosis in a broad spectrum of cancer cell lines (Ashkenazi, 2002) . Also, TRAIL exhibited potent tumoricidal activity in vivo in several mouse models of human cancers (LeBlanc and Ashkenazi, 2003) . Since BetA significantly potentiated the cytotoxic activity of TRAIL, BetA may be used in TRAIL-based therapies to enhance the efficacy of TRAIL for inhibition of tumor growth. Importantly, BetA did not reverse the lack of toxicity of TRAIL on primary nonmalignant human cells, for example, fibroblasts, indicating some tumor specificity. The underlying mechanism(s) for the differential sensitivity of malignant versus nonmalignant human cells towards the sensitization effect by BetA are presently unknown and are subject to further investigation. Notably, the cooperative effect between TRAIL and BetA was found at suboptimal concentrations of TRAIL that on their own only induced minimal apoptosis. Thus, BetA may be used in TRAIL-based therapies to reduce the doses of TRAIL required for tumor cell killing. This may be of special relevance for the use of TRAIL in cancer therapy, since some concerns about potential toxic side effects of TRAIL on normal human cells, for example, hepatocytes or astrocytes have recently been raised (Jo et al., 2000; Nitsch et al., 2000) . The loss of tumor selectivity may be related to the TRAIL preparations or to the TRAIL doses used in these studies (LeBlanc and Ashkenazi, 2003) . Therefore, lowering the TRAIL doses necessary for efficient tumor eradication, for example, by simultaneous administration of BetA, may increase the therapeutic index of TRAIL-based regimens. Also, combination treatment using low doses of each agent may be advantageous in light of the fact that high concentrations found to be active in vitro may often not be achieved in vivo. Clinically, resistance to apoptosis is a major cause of nonresponsiveness of cancers leading to treatment failure. Thus, the combination of BetA and TRAIL may be a novel strategy to enhance the efficacy of TRAIL-based therapies, which warrants further investigation.
